Market Closed -
Other stock markets
|
After market 12:57:30 pm | |||
5.64 EUR | -5.53% | 5.64 | 0.00% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.38M | Sales 2024 * | 37.83M 40.43M | Capitalization | 129M 138M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.58M | Net income 2024 * | -5M -5.34M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.02M | Net Debt 2024 * | 46.6M 49.8M | EV / Sales 2024 * | 4.64 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-13.9
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | -5.53% | ||
1 week | +15.69% | ||
Current month | +16.05% | ||
1 month | +17.50% | ||
3 months | +45.17% | ||
6 months | +26.17% | ||
Current year | +31.78% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 5.64 | -5.53% | 240 936 |
24-04-23 | 5.97 | 0.00% | 376,959 |
24-04-22 | 5.97 | +10.97% | 410,921 |
24-04-19 | 5.38 | +7.60% | 328,456 |
24-04-18 | 5 | +2.56% | 128,837 |
Real-time Euronext Paris, April 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.78% | 138M | |
+3.09% | 43.43B | |
+47.81% | 41.69B | |
+7.72% | 41.31B | |
-10.92% | 27.14B | |
+8.10% | 25.28B | |
-24.44% | 18.47B | |
+29.30% | 12.59B | |
+0.87% | 12.33B | |
+8.68% | 11.03B |
- Stock Market
- Equities
- OSE Stock